



One Health Network on Antimicrobial Resistance (AMR)

AMR epidemiological situation: ECDC update

Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Programme

Brussels, 5 February 2018

ECDC – European Centre for Disease Prevention and Control









- An agency of the European Union, located in Stockholm, Sweden
- Founded in 2005; nearly 300 employees in 2015
- Mandate to 'identify, assess and communicate current and emerging threats to human health from communicable diseases'
- European Union (EU) (28) and European Economic Area (EEA) (3) = 31 countries with a total of more than 500 million people

Antimicrobial Resistance and Healthcare- Associated Infections (ARHAI) Networks



- European Antimicrobial Resistance Surveillance Network (EARS-Net)
 - (formerly EARSS, integrated in January 2010)
- European Surveillance of Antimicrobial Consumption Network (ESAC-Net) (formerly ESAC, integrated in July 2011)
- Healthcare-Associated Infections surveillance Network (HAI-Net) (formerly HELICS / IPSE, integrated in July 2008)

Participation in ECDC networks: No. of EU/EEA countries reporting data to TESSy




Network	Type of surveillance	No. countries	Year
EARS-Net	AMR (S.aureus, E. coli, K. pneumoniae, etc.)	30	2016
FWD-Net	AMR (Salmonella spp.)	24	2015
	AMR (Campylobacter spp.)	19	
ESAC-Net	Antimicrobial consumption – Community	29	2016
	Antimicrobial consumption – Hospital sector	23	
HAI-Net	2nd PPS of HAI and antimicrobial use (incl. AMR)	28	2016-2017
	Surgical site infections (incl. AMR)	16	2015
	HAI in intensive care units (incl. AMR)	15	2015
	HAI and antimicrobial use in LTCFs (incl. AMR)	23	2016-2017
	Clostridium difficile infections	20	2016

Source: ECDC, January 2018.

Compartments of antimicrobial resistance











Surveillance Atlas of Infectious Diseases




Streptococcus pneumoniae: % of invasive isolates with resistance to macrolides, EU/EEA, 2006 & 2016






Escherichia coli: percentage of invasive isolates resistant to third-generation cephalosporins, EU/EEA, 2006 & 2016





Escherichia coli: percentage of invasive isolates resistant to fluoroquinolones, EU/EEA, 2006 & 2016









Staphylococcus aureus: % of invasive isolates with resistance to meticillin (MRSA), EU/EEA, 2006 & 2016






Klebsiella pneumoniae: % of invasive isolates with combined resistance*, EU/EEA, 2006 & 2016






Klebsiella pneumoniae: % of invasive isolates with resistance to carbapenems, EU/EEA, 2006 & 2016






Enterococcus faecium: % of invasive isolates with resistance to vancomycin, EU/EEA, 2006 & 2016





Acinetobacter spp.: % of invasive isolates with combined resistance*, EU/EEA, 2012 & 2016







European Centre for Disease Prevention and Control

An agency of the European Union




Infectious diseases & public health

News & events

Publications & data

About us Q

Home > Publications & data > Epidemic Intelligence Information System (EPIS)



Examples

- Mycobacterium chimaera cardiovascular infections linked to heater-cooler devices
- Candida auris infection
- optrA (transferable oxazolidinone and chloramphenicol resistance)

Epidemic Intelligence Information System (EPIS)











The Epidemic Intelligence Information System (EPIS) is a web-based communication platform that allows nominated public health experts to exchange technical information to assess whether current and emerging public health threats have a potential impact in the European Union (EU).

Download



EPIS - specific privacy statement - 2016 - EN - [PDF-106.53 KB]

Access Epis



European Centre for Disease Prevention and Control

An agency of the European Union



Infectious diseases & public health

News & events

Publications & data About us Q



Home > Infectious diseases & public health > Antimicrobial consumption > Surveillance and disease data > Antimicrobial consumption database

 Surveillance and disease data

Antimicrobial consumption database (ESAC-Net)

tool









The ESAC-Net interactive database provides European reference data on antimicrobial consumption, both in the community and the hospital sector. The reports of the database are provided through the European Surveillance antimicrobials in groups. Data are presented up to the fourth level of this classification.

Country overview ▶

Overview of antimicrobial consumption in Europe interactive reports per country and year

Quality indicators for consumption in the community >

Data source overview

Data source overview of antimicrobial consumption in Europe, all countries and years

Distribution by antimicrobial group >

Distribution of antimicrobial

Geographical distribution ▶

Distribution of consumption by type of antimicrobial, type of care, year

Rates by country >

Interactive reports by antimicrobial type of care year


Defined daily doses

(DDD) per 1000 inh. and per day

Country	2016	Trends in antimicrobial consumption, 2012–2016
Netherlands	10.4	-
Estonia	12.0	
Sweden	12.0	
Latvia	13.2	
Austria	13.3	
Slovenia	13.9	
Germany	14.1	
Norway	15.2	-
Hungary	15.4	
Denmark	15.9	-
Malta	16.4	
Finland	16.5	-
Lithuania	16.9	
United Kingdom	19.6	-
Bulgaria	19.8	
Croatia	20.7	
Iceland	21.0	-
Portugal	21.6†	1
EU/EEA	21.9	1
Spain	23.0†	
Slovakia	23.6	
Poland	24.0	
Ireland	24.2	
Luxembourg	25.5	-
Italy	26.9	
Belgium	27.5	
Romania	29.5*	
France	30.3	
Cyprus	33.0*	
Greece	36.3	
Czech Republic		-

Packages

per 1000 inh. and per day





- * Total care data, including the hospital sector.
- † Reimbursement data (i.e. not including consumption without a prescription and other non-reimbursed courses).

Consumption of antibiotics for systemic use (ATC group J01) in the community, EU/EEA, 2012-2016

Consumption of antibiotics for systemic use (ATC J01) in the hospital sector, EU/EEA,

2012-2016 (DDD per 1000 inhabitants and per day)

Country	2012	2013	2014	2015	2016	Trends in antimicrobial consumption, 2012–2016
Netherlands	0.96	0.95	0.95	0.98	0.97	
Hungary	1.23	1.20	1.25	1.23	1.18	~
Poland			1.43	1.43	1.36	-
Norway	1.44	1.39	1.41	1.40	1.38	1
Portugal (b)	1.46	1.64	1.55	1.57	1.58	1
Belgium	1.71	1.67	1.60	1.67	1.63	
Bulgaria	1.37	1.38	1.40	1.37	1.63	
Sweden	1.65	1.67	1.57	1.67	1.65	-
Slovenia	1.56	1.55	1.61	1.68	1.69	
Estonia	2.00	1.79	1.81	1.74	1.70	1
Luxembourg	2.02	2.00	1.81	1.78	1.73	-
Ireland	1.76	1.79	1.66	1.91	1.83	~
Croatia	1.97	1.79	1.85	1.90	1.87	1
Denmark	1.78	2.02	2.13	2.34	1.99	
EU/EEA	1.95	2.03	2.00	2.04	2.06	-
Latvia	2.24	2.28	2.24	2.24	2.10	-
France	2.12	2.17	2.20	2.18	2.19	-
Greece	1.90	2.00	2.11	2.14	2.39	
Italy	2.40	2.16	2.15	2.36	2.47	
Slovakia	2.02	2.30	2.47	2.40	2.49	
Finland (a)	2.79	2.77	2.64	2.50	2.52	
United Kingdom		2.45	2.59	2.55	2.58	
Lithuania	2.39	2.39	2.35	2.54	2.59	-
Malta	1.44	1.75	2.18	2.86	2.89	

- (a) Finland: data include consumption in remote primary healthcare centres and nursing homes.
- (b) Portugal: data relate to public hospitals only.

Consumption of last-line antibiotics in the hospital sector, EU/EEA, 2012-2016



Carbapenems

(DDD per 1000 inh. and per day)

Country	2016	Trends in consumption of carbapenems, 2012–2016
Bulgaria	0.028	
Poland	0.022	-
Netherlands	0.020	~
Latvia	0.034	
France	0.033	
Norway	0.040	
Hungary	0.048	-
Lithuania	0.053	
Slovakia	0.055	
Romania	0.059*	
Estonia	0.064	-
Sweden	0.051	
EU/EEA	0.052	1
Italy	0.040	
Finland (a)	0.090	
Belgium	0.063	
Slovenia	0.071	-
United Kingdom	0.068	1
Croatia	0.084	-
Denmark	0.079	1
Luxembourg	0.102	
Ireland	0.081	
Malta	0.113	
Cyprus	0.141*	
Portugal (b)	0.124	
Greece	0.180	

Polymyxins (mainly colistin)

(DDD per 1000 inh. and per day)

Country	2016	Trends in consumption of polymyxins, 2012–2016
Finland (a)	0	
Lithuania	0	
Norway	0.001	
Sweden	0.001	
Latvia	0.002	
Netherlands	0.002	
Bulgaria	0.004	
Estonia	0.005	-
Luxembourg	0.005	-
Denmark	0.006	1
Ireland	0.006	
United Kingdom	0.006	/
France	0.007	
Belgium	0.008	1
Slovenia	0.008	
Hungary	0.010	
EU/EEA	0.016	
Malta	0.016	
Croatia	0.017	\
Cyprus	0.019*	1
Portugal (b)	0.022	~
Romania	0.026*	
Italy	0.027	
Poland	0.034	
Slovakia	0.035	
Greece	0.102	

- * Cyprus and Romania: total care data, including consumption in the community. These data were not used to calculate the EU/EEA population-weighted average.
- (a) Finland: data include consumption in remote primary healthcare centres and nursing homes.
- (b) Portugal: data relate to public hospitals only.



European Centre for Disease Prevention and Control

An agency of the European Union



Infectious diseases & public health

News & events

Publications & data About us Q.

Publications & data
 Directory: Guidance on prevention and control



Directory of online resources for prevention and control of antimicrobial resistance (AMR) and healthcare-associated infections (HAI)









The directory lists strategies, guidance documents and training courses on the prevention and control of antimicrobial resistance and healthcare-associated infections available online. These documents were published by ECDC, EU/EEA Member States, international and national agencies and professional societies to support healthcare professionals, hospital administrators and public health professionals. In addition, the directory lists ongoing research projects and their corresponding websites.

ECDC welcomes suggestions and further information on existing guidance. Comments can be provided to: arhal@ecdc.europa.eu.

Guidelines for specific infections and organisms

Healthcare-associated infections		Multidrug-resistant organisms
7. 图	Carbapenem-resistant Enterobacteriaceae (CRE)
7/9/1	Methicitlin-resistant Staphylococcus aureus	(MRSA)

Prevention and control measures in healthcare settings

Strategies, action plans, projects	Prudent use of antibiotics	Infection and control measures	Training
Antimicrobial resis	tance strategies and action plan	5	
Projects on antimi	robial resistance and healthcare	-associated infections	



National strategies and action plans on antimicrobial resistance



GLOBAL

WORLD HEALTH ORGANIZATION (WHO) AND WHO MEMBER STATES

- Gratual authors gave, and perhaps related in commune (2016);
- Vanial to Evening rational action plans, through retrieval action plans, and support twill including beneficial (2016);

EUROPE

WHO/EUROPE MEMBER STATES

. Existeen stange actor plus on artificial resistance (2011) in

COUNCIL OF THE EUROPEAN UNION (EU)

 Captal incurrenession of 15 Novymber (001 on the prodest use of principoolal sports in human medicine (2007/THCL)

EUROPEAN COMMISSION

- * European Des Health Action Plan against Arthrespotal Humblance (AMH) (Computer Commission, 2017) of
- Action plan against the rang threats from Antinomical Remotercy (COM (2011) 742) in
- · Action on antimorphist reachance of EXF levels.

EU/EEA MEMBER STATES

ALISTRIA

National oction on antimicrobial resultance (Ministry of Health, 2014)
 National Octoorage DV Arthodographics

CZECH REPUBLIS

Action Plan of the National Artitivotic Programme for the period 2011-2013 (Ministry of Hooffs, 2011).
 Action Plan Manufatho artitivotacións programs pro osciolis 2011-2013 (Manufatho poliumbetts, 2011).

CYPRUS

National strategy of Cyprus against microbial resistance to artibiotics (Winestry of Health, 2012).
 Ethnis Exproved National years Available for the Applicants, Avency, one Artibiotics of

DENMARK

 National action plan on aritimicrobial resistance (Indensign- og Sundhodsministeret, Ministeret for Federane, Landling og Fiskel, 2010)

Fados anticola, og mislemhandingsplass

FRANCE

Interview to contrast to controlling antinionabilities controlling of Solidanties and Health, 2016).

GERMANY

National action plan on prevention of antincirollal sociations (the Bunderregionurg, 2015)
 CART 2000 — Authoritis Prosistances bestampter transferonce Messan until fair of EART 2000—Papeling antillistic resistance for the goal of field homeon and service Chapter variances.

GREECE

- National Action Plan "Proceeded" (Hoteinic Contin for Disease Contint and Provention, 2016).
 Let'de Goding, "Unixpointing" a
- National Action Plan (2006-2012) (Hellient: Currier for Disease Covins and Provinties, 2008)
 Direct 2 of the Equitor, year top: Americanisms ray, Mapopleadig America; one Americanist see year (regulations in National Character, Verynamick Variety, 2006-2012)

UREXAND

Instand National Action Plan on Antimicrobial Resistance 2017 2020 – INAP (Department of Health, 2617).
 Instand National Action Plan on Antimicrobial Resistance 2017 2020 – Infahry

ITALY

- Rational Plan against Arbinosobial Husintance 2017-2020 (Ministry of Health, 2017).
 Plans Rassmath & Contrasto dell'Ambandotto Resultatus (PHCAR) 2017-2020.
- Opuscole PTICATI Flore nagrange di compato dell'adescribez momenta 2017-2020 di
- Leafer PNCAVI National action plan on antimicrotical resistance 2017 2425 --

NETHERLANDS

Coulch National Action Plan on AMR (Membry of Health, Welfare and Sport, 2011)
 Epimetrial met corporal artifaction membranes
 Letter to participant about the opposite to artifactio (Australia)

NORWAY

- Action pan against artibiotic resistance in healthcare thetise- og ensergadiguartementet, 2015).
 Handlinggrån mit urobooklasesstens i handlingsten in
- National strategy against antibiotic resistance (2015–2020) (Nonvegian Ministries, 2015).
 Ausgeral of allog that Artificializations from 2015–2020 (

National Strategy squared Architectic Manufactor 2015-2525 (English removing)

PORTUGAL

 Programme on prevention and control of effection and antimicrobial resistance (Directorals General of Health, Metalty of Health, 2012/Programs on Prevention a Control on integlan in Resistance and instrumentations Construction Programs (Resistance on Prevention of Controls de Integlan on the Resistance and Antimicrobians)

(PPCIRA) (CQUIDES) em 311 x2014 e

 National Adian Plan for the Reduction of Artibidis Use in Avinato (Fead and Veterinary Desclarate-General, Milestry of Approximate Sea, 2813)
 Plans de Aján teoceas para a Redução do 11so de Artibidisco nos Avansos e

OR .

Stodegic Action Plan to reduce the mix colection and dispensionates of artificials resistance (Ministry of Health, book) Services and Equaty, Spanish Agency of Modernion and Medical Devices, 2014;
 Plan subalitype of a accellenges instance of marge of selectivity (dispension) to especialise in the artificial formation plan is the prevention of the artificial habitance selection and dispensions of artificial medical control of artificial formation of artificial fo

· Phot Macional de Manufaccia a un Aptitablica (TRIAN) -

SWEDEN

Swedish strategy to combat artifactic resistance (Government of Sweden, 2010)

Second strategy to combat artificity reconstruct (2016) a Second strategy for adopted root artificial artificial

Sweet states for attack out artisus are store - Slage (2010)

 National stategy on prevention of antimicrobial resistance and healthcare-especialed infections (Government of Sueden, 2005)

Studios for all connective artists not artificial accommendate specimen (2005)-

UNITED KINGDOM

- SR 5 Year Anthropous Pountainos (ASPO Sharing) 2013–2018. Annual program report and expressorations page, 2014 (184 Conventions, 30 14) a
- UK Five Year Artistacested Manifestor Studying 2013 to 2016 (Department of Hugh); 2013/d

COUNTRIES OUTSIDE THE EU/EEA

CANADA

- Addressoon Resistance and this in Carada. A Federal Franceson for Action (Development of Carada. 2914).
- Federal Action Plan on Addrescribed Resistance and their in Canado: Building on the Federal Framework for Action (Public Health Agency of Canada, 2015) a

SWITZERLAND

- Studegy on Artificity Forestoria Switzerson (The Faderal County, 2016).
- Strategy Antibiotiss recorders on Schweit (Ber Bundereck, 2015).
- . Displays furthermissionic fluxus (Le Consel Valles), 2015) of

UNITED STATES OF AMERICA

- + Executive Order: Commuting Antibodic Resident Bacterio (The Wildle Hoose, 2014) e
- . National Stategy for Combatting Ambasis Provided Suchels (The Wide House, 2014)





European Centre for Disease Prevention and Control

An agency of the European Union



Infectious diseases & public health

News & events

Publications & data About us

Home > Infectious diseases & public health > Antimicrobial resistance > Preparedness > ECDC Country visits reports



ECDC Country visits reports

National strategies and action plans

Country visits reports









Following an official invitation by the Member States, an ECDC team conducts visits and meetings to discuss AMR issues in the country with the overall objective of providing an evidence-based assessment of the situation regarding prevention and control of AMR through prudent use of antibiotics and infection control. The page shows the ECDC country visit reports.

Italy





ECDC country visit to Italy to discuss antimicrobial resistance issues

mission report - 12 Dec 2017

An ECDC team conducted visits and meetings to Italy on 9-13 January 2017 to specifically discuss and assess the situation in the country regarding prevention and control of AMR.

Observations from this ECDC country visit confirm that the AMR situation in Italian hospitals and regions poses a major public health threat to the country. If the current trends of carbapenem resistance and colistin resistance in gram-negative bacteria such as Klebsiella pneumoniae and A. baumannii are not reversed, key medical interventions will be compromised in the near future.

ECDC country visit to Italy to discuss antimicrobial resistance issues -EN - [PDF-573.62 KB]

Antibiotic/Antimicrobial resistance (AMR) | Italy



A forward look



2018

- Annual update on AMR and antimicrobial consumption in humans in the EU/EEA. Both data from EARS-Net and ESAC-Net (NEW) as part of the ECDC ATLAS, EARS-Net 2017 report, ESAC-Net 2017 HTML format on ECDC website (NEW) (October 2018)
- **NEW** Burden of antimicrobial resistance (AMR) for the EU/EEA (November 2018)
- **NEW** ECDC point prevalence surveys of HAIs, AMR and antimicrobial use in European acute care hospitals and in long-term care facilities, 2016-2017 (November 2018)
- **NEW** Launch of project on whole genome sequencing (WGS)-based surveillance of carbapenem- and/or colistin-resistant *Enterobacteriaceae* (EURGen-Net)

2019

NEW - ECDC comprehensive AMR report (November 2019)

Thank you!





18 November 2018

E-mail: <u>EAAD@ecdc.europa.eu</u>

Website: https://antibiotic.ecdc.europa.eu

Facebook: EAAD.EU

Twitter: @EAAD_EU (#EAAD)
Global Twitter: #AntibioticResistance



WORLD ANTIBIOTIC AWARENESS WEEK

